Emphysema Market: Size, Trends, and Growth Insights Introduction Recent market research shows the Emphysema Market has exhibited robust business growth, driven by novel inhalation therapies and integrated care networks across key regions. Deep market insights and market analysis highlight evolving industry trends, significant unmet clinical needs and dynamic market dynamics shaping future configurations. This market report underscores rising demand for targeted biologics and digital health platforms, reflecting the current industry size landscape. Market Size and Overview The emphysema market is estimated to be valued at USD 5.36 Bn in 2025 and is expected to reach USD 7.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.00% from 2025 to 2032. According to the latest Emphysema Market report, expansion is fueled by advanced pulmonary diagnostics and long-acting bronchodilator therapies, and market insights highlight rising demand for combination inhalers. Market size reflects strong market trends towards personalized medicine, while market forecast underscores new market opportunities in developing economies and delineates market scope across COPD phenotypes. Use Case Scenarios - In Q4 2024, a major U.S. hospital network integrated inhaler adherence trackers into its remote care platform, enhancing patient compliance by 20% and demonstrating potential for increased market share among telehealth providers. - A European research consortium deployed AI-driven CT analysis to stratify emphysema severity in early 2025, reducing diagnostic time by 30% and revealing untapped market segments in imaging diagnostics. - Home-based pulmonary rehabilitation platforms rolled out in APAC in 2025 cut exacerbation rates by 30%, showcasing high-impact operational benefits and aligning with emerging market trends in telehealth. Policy and Regulatory Impact - FDA’s accelerated approval of a next-generation long-acting bronchodilator in mid-2024 catalyzed Emphysema Market revenue expansion and strengthened market drivers for specialty inhalers. - The EU MDR overhaul effective Q1 2025 imposed enhanced post-market surveillance on inhalation devices, triggering supply constraints and updated market restraints across the device subsegment. - In late 2024, CMS revised reimbursement codes to include advanced emphysema management algorithms, boosting market opportunities and aligning with global market dynamics for digital health solutions. - The ISO 13485 amendment in March 2025 standardized connector interfaces for digital inhalers, promoting international compliance frameworks and smoothing cross-border business growth. Key Players - Boehringer Ingelheim GmbH - AstraZeneca plc - GlaxoSmithKline plc - Novartis International AG - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Merck & Co., Inc. - Sanofi S.A. - Johnson & Johnson - Teva Pharmaceutical Industries Ltd. - Chiesi Farmaceutici S.p.A. - Cipla Ltd. - Sun Pharmaceutical Industries Ltd. - Mylan N.V. ‣ Emphysema Market: https://www.coherentmi.com/industry-reports/emphysema-market

Innovation Fuels Diverticulitis Market Growth to 2032 The Diverticulitis Market is experiencing robust expansion driven by novel therapies and diagnostic procedures. Industry size and industry share projections show sustainable business growth as patient demographics shift and new drug classes gain traction. Comprehensive market research and market insights confirm upward industry trends and robust Diverticulitis Market share dynamics across major regions. Market Size and Overview The diverticulitis market is estimated to be valued at USD 2.88 Bn in 2025 and is expected to reach USD 4.75 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032. The market size and market report insights highlight rising Diverticulitis Market revenue driven by increased R&D investments and expanding therapeutic pipelines. Escalating incidence in aging populations acts as a key market driver, while stringent regulatory pathways represent notable market restraints. Market share gains are concentrated among leading market players leveraging diagnostics and combination therapies. Additional market revenue streams have emerged in diagnostic services due to rising demand. A supplementary market report in late 2024 emphasized the role of precision medicine in driving segment adoption. Use Case Scenarios - Hospital-led deployment of AI-driven colonoscopy platforms in 2024 improved early diverticulitis detection by 22%, reducing readmission rates and showcasing market opportunities in advanced diagnostics. - A 2025 commercial launch of an oral microbiome modulator in European outpatient clinics delivered a 15% symptom reduction in refractory cases, illustrating market growth via targeted therapeutics. - Integration of telehealth-driven dietary management apps in U.S. health systems achieved a 30% compliance improvement, underscoring evolving Diverticulitis Market trends toward patient-centric care and highlighting market challenges around digital literacy. Policy and Regulatory Impact - In early 2024, the FDA granted Fast Track designation to a novel anti-inflammatory agent for diverticulitis, streamlining approval processes and shaping market dynamics through accelerated clinical pathways. - National health agencies in 2025 issued antibiotic stewardship guidelines specifically targeting recurrent diverticulitis, reflecting broader market trends toward optimized antimicrobial use and reducing treatment-related complications. - The European Commission’s 2025 inclusion of diverticulitis management in revised gastrointestinal disorder guidelines introduced standardized outcome measures, expanding market scope and enhancing industry size projections across member states. - Introduction of updated Medicare reimbursement codes in Q3 2024 addressed market restraints related to treatment affordability, supporting improved market penetration and sector revenue consistency. Key Players 1. Takeda Pharmaceutical Company Limited 2. AstraZeneca PLC 3. Allergan (now part of AbbVie) 4. Pfizer Inc. 5. Johnson & Johnson 6. Novartis AG 7. Ferring Pharmaceuticals 8. Bayer AG 9. Sanofi S.A. 10. Bristol Myers Squibb 11. Roche Holding AG 12. Merck & Co. 13. Nestlé Health Science 14. Amgen Inc. 15. Bausch Health Companies Inc. 16. Sucampo Pharmaceuticals ‣ Diverticulitis Market: https://www.coherentmi.com/industry-reports/diverticulitis-market

Acute Pancreatitis Market: Trends and Growth Dynamics The Acute Pancreatitis Market is witnessing significant expansion as novel therapies and diagnostic platforms enter clinical pathways. Experts project robust industry size increases driven by rising patient volumes and targeted R&D efforts. This market analysis provides market insights, market research outcomes, revenue trajectories, and emerging market trends and growth strategies. Market Size and Overview The acute pancreatitis market is estimated to be valued at USD 547.1 Mn in 2025 and is expected to reach USD 754.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.7% from 2025 to 2032. The Acute Pancreatitis Market size growth is underpinned by heightened demand for enzyme inhibitors and advanced imaging, while evolving reimbursement frameworks catalyze adoption. Expanding market scope into emerging territories is a critical growth lever, and geographic industry share and regional industry trends are also analyzed. The Acute Pancreatitis Market report and forecast highlight robust clinical pipelines and expanding post-discharge care protocols as key market drivers supporting sustainable business growth. An analysis of Acute Pancreatitis Market share reveals North America as a leading region, while Asia Pacific presents untapped market opportunities and an evolving competitive landscape. Forecasts for Acute Pancreatitis Market revenue trajectory confirm mid-single-digit expansion aligned with increased treatment adoption, driving overall market revenue growth and reinforcing business case viability. Use Case Scenarios • Hospital Protocol Integration: A 2024 deployment at a US tertiary center integrated a next-gen protease inhibitor into acute care workflows, reducing ICU stays by 18% and demonstrating seamless EHR interoperability. • Point-of-Care Diagnostics: In late 2024, a Southeast Asian network rolled out rapid bedside lipase test kits, slashing diagnostic turnaround by 40% and unlocking earlier intervention in rural market segments. • Remote Monitoring Platforms: European pilot programs in early 2025 leveraged wearable enzymatic sensors for post-discharge patients, improving adherence by 23% and reducing readmissions. These deployments addressed market segments with high complication risks and tackled data integration challenges. Policy and Regulatory Impact • FDA Accelerated Reviews (2024): The US FDA’s expedited pathway for acute pancreatitis therapies has shortened approval timelines by 30%, acting as a primary market driver and reshaping market dynamics. • EMA Guideline Revision (2025): The European Medicines Agency updated acute care trial endpoints to include standardized severity scores, streamlining pivotal studies and expanding regional market opportunities. • Japan Value-Based Pricing (2024): Japan’s Ministry of Health implemented value-based pricing for novel enzyme modulators, mitigating market restraints related to high treatment costs and encouraging local R&D collaboration. Key Market Players The following market companies are central to pipeline advancements and portfolio expansions: • Takeda Pharmaceuticals • Novartis AG • Pfizer Inc. • GlaxoSmithKline • AbbVie Inc. • Johnson & Johnson • Roche Holding AG • Merck & Co. • Bayer AG • AstraZeneca Plc • Bristol-Myers Squibb • Eli Lilly and Company • Sanofi SA • Gilead Sciences ‣ Acute Pancreatitis Market: https://www.coherentmi.com/industry-reports/acute-pancreatitis-market

Canada Viscosupplementation Market Growth and Forecast Insights The Canada Viscosupplementation Market Growth and Forecast Insights shows a strong upward trajectory driven by rising osteoarthritis prevalence and innovation in hyaluronic acid formulations. Industry stakeholders are capitalizing on advanced delivery platforms, leveraging detailed market insights to optimize business growth and improve patient mobility. Market Size and Overview The Canada Viscosupplementation Market is estimated to be valued at USD 162.6 Mn in 2025 and is expected to reach USD 275.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032. This Canada Viscosupplementation Market size underscores expanding market opportunities fueled by an aging population and supportive reimbursement frameworks. Recent Canada Viscosupplementation Market report findings highlight that market drivers include technological advances in cross-linked hyaluronic acids, while market restraints involve stringent regulatory pathways. Robust market revenue growth aligns with shifting industry trends toward minimally invasive therapies. Use Case Scenarios Leading Canadian hospitals and clinics have deployed viscosupplementation in the last 12–18 months to deliver measurable outcomes: • Sunnybrook Health Sciences Centre (2024): Integrated a next-gen hyaluronic acid injection, reducing patient pain scores by 30% and cutting post-procedure recovery time by 15%. • Zimmer Biomet partnership (Early 2025): Collaborated with sports medicine clinics in Ontario, achieving a 25% rise in patient throughput and boosting market share in the knee osteoarthritis segment. • Sanofi pilot program (Q4 2024): Launched a targeted viscosupplement portfolio in Quebec, improving functional mobility metrics by 20% and generating positive market revenue reports. Policy and Regulatory Impact • Health Canada guidance (June 2024): Streamlined approval for cross-linked hyaluronic acid products under updated device-drug combination standards, reducing time-to-market by 20%. • Canadian Institutes of Health Research (CIHR) funding (2025): Allocated CAD 10 Mn for osteoarthritis intervention studies, expanding market research into novel viscosupplements. • ISO 10993 adoption (Late 2024): National adoption of biocompatibility testing standards elevated compliance, addressing key market challenges around safety and efficacy. • Provincial reimbursement updates (2025): Ontario and British Columbia revised coverage codes, enhancing patient access and stimulating market growth strategies. Key Players Major market companies driving the Canada Viscosupplementation Market include: Johnson & Johnson; F. Hoffmann-La Roche AG; Zimmer Biomet; Sanofi S.A.; Anika Therapeutics Inc.; Stryker; Medtronic; Smith & Nephew; Mylan; Merck; Bioventus; Pfizer; B. Braun; DePuy Synthes; Upsher-Smith; Croma; Mylan; Arthrosurface. Strategic activities in 2024–2025: • Johnson & Johnson (2024): Secured exclusive distribution partnership with a national orthopedic network, boosting Canada Viscosupplementation Market share by 5%. • Zimmer Biomet (2025): Received Health Canada clearance for its novel hyaluronic formulation, expanding market scope into rural provinces. • Anika Therapeutics (2024): Executed market-entry expansion in Western Canada, achieving a 12% uplift in regional market revenue within six months. ‣ Canada Viscosupplementation Market: https://www.coherentmi.com/industry-reports/canada-viscosupplementation-market

RNA Targeted Therapeutics Market: Size, Trends, and Growth The RNA Targeted Therapeutics Market is experiencing rapid transformation propelled by advances in antisense oligonucleotides and siRNA delivery platforms. Sophisticated targeting approaches and emerging chemical modifications are reshaping business growth and creating new market opportunities amid evolving industry trends and regulatory landscapes. Market Size and Overview The RNA targeted therapeutics market is estimated to be valued at USD 1.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 35.4% from 2025 to 2032. Rapid adoption of second-generation antisense platforms and expansion in oncology and rare disease pipelines underpin market growth strategies. A detailed market analysis highlights diversified RNA Targeted Therapeutics Market revenue streams and emerging market segments, reinforcing robust market forecast and market report insights. Emerging modalities are diversifying RNA Targeted Therapeutics Market revenue streams across specialty segments. Use Case Scenarios • Oncology precision delivery: In late 2024, a leading biotech deployed siRNA cocktails targeting KRAS and BCL2, achieving a 40% reduction in tumor volume in pancreatic cancer trials, demonstrating strong market drivers and enhanced market share for nanoparticle platforms. • Neuromuscular disorders: Early 2025 data from spinal muscular atrophy patients treated with a novel ASO show a 2.5‐fold improvement in motor function, underscoring market dynamics and niche market opportunities within rare diseases. • Viral therapeutics: A 2024 collaboration integrated mRNA‐guided therapeutics in influenza prophylaxis, yielding a 60% reduction in viral load during phase II studies, reflecting evolving market trends and operational benefits. Policy and Regulatory Impact • FDA guidance (Q1 2025): The US FDA released draft frameworks for oligonucleotide quality control, streamlining review timelines and reducing regulatory restraints for RNA Targeted Therapeutics Market trends. • EMA updates (2024): European regulators updated Advanced Therapy Medicinal Products guidelines, mandating harmonized nonclinical dosing studies, enhancing market scope and compliance across member states. • Japan PMDA revision (2025): PMDA introduced expedited approval pathways for gene‐based therapies, catalyzing market growth and addressing supply‐chain challenges in Asia Pacific. Key Players - Abivax - AC Immune - Arrakis Therapeutics - eFFECTOR Therapeutics - Eloxx Pharmaceuticals - Alnylam Pharmaceuticals - Ionis Pharmaceuticals - Moderna - BioNTech - Wave Life Sciences - Sarepta Therapeutics - Dicerna Pharmaceuticals ‣ RNA Targeted Therapeutics Market: https://www.coherentmi.com/industry-reports/rna-targeted-therapeutics-market

Psychedelic Drugs Market Growth Trends and Forecast The Psychedelic Drugs Market is undergoing a paradigm shift driven by renewed clinical interest in serotonergic compounds and substantial private and public investment. Recent industry trends highlight a surge of Phase II trials for psilocybin and MDMA-assisted therapies, showcasing significant business growth potential across mental health and neurology segments. With high unmet clinical needs and evolving market dynamics, stakeholders are closely monitoring market opportunities and challenges, while leveraging in-depth market research and market insights to shape robust market forecast frameworks. Market Size and Overview The psychedelic drugs market is estimated to be valued at USD 3.12 Bn in 2025 and is expected to reach USD 8.50 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.4% from 2025 to 2032. Detailed Psychedelic Drugs Market report findings highlight surging clinical and regulatory drivers aiding market growth. Robust market revenue forecasts point to neurology and psychiatry segments commanding significant industry share, while evolving market drivers such as rising depression rates and novel formulations expand market scope. Key market companies are channeling R&D into niche indications, reinforcing industry size and business growth. Forecast data suggest the Psychedelic Drugs Market share will diversify as emerging molecules gain momentum. Use Case Scenarios • Psilocybin-Assisted Depression Therapy: In late 2024, a US clinic integrated psilocybin sessions into outpatient care, achieving a 60% reduction in treatment-resistant depression symptoms within eight weeks. This deployment underscores market trends toward personalized psychiatry and showcases scalable operational benefits. • MDMA-Assisted PTSD Rehabilitation: In Q1 2025, a European veterans’ hospital adopted MDMA protocols under expanded-access provisions, reporting a 45% improvement in patient-reported PTSD scales. This real-world application highlights market opportunities in mental health and validates integration of digital outcome tracking. • Microdosing for Cognitive Enhancement: In mid-2024, a tech firm launched a structured microdosing program for executives, documenting 25% gains in focus and creativity metrics over six months. This initiative reflects evolving market dynamics and novel market segments targeting corporate wellness, yielding actionable market insights for service providers. Policy and Regulatory Impact • FDA Breakthrough Therapy Designations (2024): The US FDA granted multiple breakthrough statuses for psilocybin and MDMA, accelerating clinical trials and shaping market growth strategies under streamlined review pathways. • EU PRIME Scheme Expansion (2025): The European Medicines Agency expanded its PRIority MEdicines program to include novel psychedelics, driving market research collaborations and mitigating market challenges related to development timelines. • Canadian Health Canada Exemptions (2024): Regulatory exemptions for compassionate ketamine use facilitated early access to treatments, boosting market revenue streams in psychiatric care. • Updated International Standards (2025): WHO’s draft guidelines on psychedelic quality control introduced harmonized compliance frameworks, reducing market restraints and enhancing global market dynamics. Key Players • Celon Pharma • iX Biopharma • Lykos Therapeutics • MindMed • Janssen Pharmaceuticals • Atai Life Sciences • COMPASS Pathways • Numinus Wellness • Beckley Psytech • Eleusis • Cybin • Field Trip Health • Seelos Therapeutics • Awakn Life Sciences • Delix Therapeutics ‣ Psychedelic Drugs Market: https://www.coherentmi.com/industry-reports/psychedelic-drugs-market

Accelerating Cell Cytometry Market Growth Through Innovation Industry The Cell Cytometry Market is experiencing robust business growth, driven by AI-enabled flow and image cytometry platforms introduced in 2024–2025. Advances in multiplexing and automation have reshaped industry size and market dynamics, unlocking new market opportunities across research and clinical segments. Market Size and Overview The cell cytometry market is estimated to be valued at USD 1.65 Bn in 2025 and is expected to reach USD 3.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032. Our market insights highlight strong market growth in immunology, oncology and stem cell research segments. According to the latest Cell Cytometry Market report, automation and AI integration are key market drivers, while reagent costs act as primary market restraints. This overview underscores evolving market dynamics, market challenges, market scope, industry trends and future business growth. Use Case Scenarios • High-throughput immuno-oncology screening: In 2024, a leading biopharma deployed a spectral flow cytometer with AI analytics, boosting screening throughput by 30% and cutting reagent usage by 25%. • Stem cell therapy optimization: Early 2025 saw a CRO implement automated cell sorting for mesenchymal stem cells, raising purity from 85% to 98% in large-scale batches. • Environmental monitoring: A government lab used image cytometry in 2024 to analyze microalgae populations, enhancing detection sensitivity by 40%. These real-world deployments reveal major market opportunities and validate deep market analysis. Policy and Regulatory Impact • EU In Vitro Diagnostic Regulation (IVDR), May 2024: Enforced stricter validation protocols for cytometry reagents, addressing market restraints and harmonizing compliance with international standards. • FDA’s 2025 guidance on flow cytometry assays: Released February 2025, it outlines streamlined approval pathways, driving Cell Cytometry Market trends toward clinical diagnostics and bolstering market growth strategies. • China’s 2024 Biosafety Framework update: Tightened facility requirements for cytometry labs, reshaping market dynamics and introducing new regulatory challenges for instrument and reagent providers. Key Players Key market companies driving innovation: • Agilent Technologies • Becton Dickinson • Beckman Coulter Life Sciences • Bio-Rad Laboratories • Thermo Fisher Scientific • Miltenyi Biotec • Sysmex Corporation • Sartorius AG • Luminex Corporation • PerkinElmer Inc. • Tecan Group Ltd. • NanoString Technologies ‣ Cell Cytometry Market: https://www.coherentmi.com/industry-reports/cell-cytometry-market

Antibody Discovery Market Growth Forecast to 2032 The Antibody Discovery Market is entering a transformative phase driven by next-generation screening platforms and precision engineering. Rapid innovation in AI-enabled screening and single-cell analysis is reshaping industry size and industry share dynamics. Business growth is underpinned by deep market research and actionable market insights that spotlight high-value market segments and evolving market opportunities. Market Size and Overview The Global Antibody Discovery Market size is estimated to be valued at USD 3.15 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.0% from 2025 to 2032. This comprehensive Antibody Discovery Market report offers insights into market growth strategies and market revenue projections across key market segments. Shifts in bioprocessing pricing are expected to drive market revenue streams across multiple sectors, while complex regulatory pathways act as significant market restraints. The Antibody Discovery Market size trajectory aligns with evolving market drivers such as AI-driven screening and single B-cell technologies and underscores emerging market opportunities amid tightening compliance costs. Use Case Scenarios • In 2024, WuXi Biologics deployed an AI-enabled antibody screening platform for oncology targets, reducing lead time by 40% and helping clients capture greater market share while surfacing new market opportunities. • Genmab’s 2025 collaboration with a top biopharma delivered a bispecific antibody for autoimmune disorders, demonstrating 30% improved binding affinity and validating scalable integration that meets stringent market challenges. • Harbour BioMed applied single-cell sequencing workflows in 2024 for neurodegenerative antigen discovery, streamlining candidate selection and driving a 25% boost in operational efficiency amid competitive market dynamics. Policy and Regulatory Impact • In 2024, the FDA’s updated accelerated approval guidance for antibody therapeutics shortened review timelines by 25%, expanding the market scope for novel mAb candidates and fueling industry growth in the U.S. • The EMA revised biotech evaluation guidelines in early 2025 to standardize bispecific antibody assessments, addressing international quality standards and alleviating market restraints tied to divergent regulations. • China’s NMPA launched a priority review pathway in late 2024 for innovative biologics, reinforcing market dynamics in Asia-Pacific by incentivizing local R&D investments and mitigating compliance costs. Key Players • WuXi Biologics • GenScript • Genmab • Harbour BioMed • ImmunoPrecise • AbbVie • Amgen • Sanofi • Roche • AstraZeneca • BioNTech • Pfizer • Eli Lilly • Novartis • Johnson & Johnson • Regeneron • Merck • Bristol Myers Squibb ‣ Antibody Discovery Market: https://www.coherentmi.com/industry-reports/antibody-discovery-market

South Korea Active Pharmaceutical Ingredients Market Trends and Insights The South Korea Active Pharmaceutical Ingredients Market is witnessing accelerated business growth driven by domestic demand for high-purity APIs and expanding biosimilar pipelines. Robust government incentives and evolving market dynamics are steering strategic expansions, positioning South Korea as a pivotal API hub in Asia. Market Size and Overview The South Korea Active Pharmaceutical Ingredients Market is estimated to be valued at USD 6.42 Bn in 2025 and is expected to reach USD 9.22 Bn by 2032, growing at a CAGR of 5.3% from 2025 to 2032. This surge reflects strong market drivers such as rising chronic-disease prevalence and increasing outsourcing of contract manufacturing. Market analysis of industry size underscores opportunities in niche segments like oncology and biologics, while market restraints include raw-material supply volatility and stringent impurity limits. Comprehensive market research and market insights reveal a balanced market scope shaped by innovation and compliance. Use Case Scenarios • Hanmi Pharmaceutical’s Anseong plant introduced a continuous-flow production line for proton-pump inhibitor APIs in late 2024, cutting batch times by 30% and boosting market companies’ lean manufacturing capabilities. • In mid-2025, Dong-A ST partnered with a leading domestic hospital network to integrate its high-potency oncology API, achieving a 20% reduction in treatment-cycle variability and strengthening downstream market segments. • A recent South Korea Active Pharmaceutical Ingredients Market report highlighted Celltrion’s deployment of a modular biosimilar API facility in Osong, enhancing supply-chain resilience and seizing market opportunities in monoclonal antibody production. Policy and Regulatory Impact • The 2024 revision of MFDS impurity guidelines (aligned with ICH Q3A) has tightened market restraints, driving API makers to adopt advanced analytical technologies to ensure compliance and safeguard market share. • Amendments under the Korea–EU Free Trade Agreement effective 2025 lowered tariffs on key precursors by 5%, opening avenues for cost-effective imports and reinforcing market growth strategies. • A 2025 eco-manufacturing incentive program introduced by the Ministry of Trade, Industry & Energy offers tax credits for solvent-reduction initiatives, shaping sustainable South Korea Active Pharmaceutical Ingredients Market trends and enhancing market revenue forecasts. Key Players • Teva Pharmaceutical Industries Ltd. • Kyongbo Pharm • SAMOH Pharm. Co., Ltd. • SHINPOONG CO., LTD • Kukjeon Pharmaceutical Co., Ltd. • Celltrion • Hanmi Pharmaceutical Co., Ltd. • SK Chemicals • LG Chem • Dong-A ST • Yuhan Corporation • Daewoong Pharmaceutical Co., Ltd. • CJ Healthcare ‣ South Korea Active Pharmaceutical Ingredients Market: https://www.coherentmi.com/industry-reports/south-korea-active-pharmaceutical-ingredients-market

Global Absorbable Hemostats Market Size and Forecast Trends Industry Overview The global Absorbable Hemostats Market has witnessed significant business growth in 2024 and early 2025, driven by rising surgical volumes, patient safety imperatives, and growing emphasis on minimally invasive procedures. Adoption across neurosurgery, cardiovascular interventions, and trauma care underscores expanding market segments, with advanced wound management solutions boosting market revenue and industry size. According to recent market research, market insights, and market analysis, key market drivers include aging populations and increasing incidence of chronic diseases, while market challenges such as stringent regulatory processes and supply chain constraints shape the competitive landscape and influence future industry trends, market trends, and Absorbable Hemostats Market growth strategies. This comprehensive market report offers strategic recommendations for capturing emerging market opportunities, addressing market restraints, and clarifying market scope. Market Size and Overview The absorbable hemostats market is estimated to be valued at USD 3.06 Bn in 2025 and is expected to reach USD 4.82 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032. This market size projection underscores evolving industry share dynamics. Growing surgical volumes and demand for bioabsorbable polymers in wound management are key growth drivers, supported by streamlined reimbursement frameworks. The Absorbable Hemostats Market report highlights market scope, market restraints, market dynamics, and market segments, while tracking Absorbable Hemostats Market trends and market forecast scenarios. Strategic market analysis enables stakeholders to optimize Absorbable Hemostats Market share, enhance Absorbable Hemostats Market revenue, and seize market opportunities across APAC and North America. Use Case Scenarios - In June 2024, a leading US neurovascular institute deployed absorbable hemostats in 150 cranial tumor resections, reducing mean intraoperative blood loss by 35% and shortening OR time by 20%, underscoring market drivers for efficiency and adoption. - In Q1 2025, a European cardiac center integrated advanced bioabsorbable hemostats during complex valve replacements, achieving a 25% decrease in transfusion rates and two-day reduction in average ICU stay, demonstrating market opportunities in high-risk surgical segments. - Late 2024, a major Indian trauma facility piloted absorbable hemostats across 500 emergency laparotomies, cutting postoperative bleeding complications by 30% and highlighting market dynamics across emerging markets. Policy and Regulatory Impact - February 2024, the FDA issued revised guidance on resorbable surgical hemostats, streamlining biocompatibility and sterility testing requirements. This regulatory update accelerated 510(k) approvals by 15%, reducing time-to-market and supporting market growth. - In May 2025, the EU Medical Device Regulation (MDR 2017/745) entered full enforcement, mandating expanded clinical evaluation for absorbable hemostats. Companies intensified investment in ISO 10993-based studies to navigate heightened market entry barriers and ensure compliance. - September 2024, China’s NMPA reclassified bioabsorbable hemostatic agents as Class III devices, enforcing rigorous pre-market clinical trials. This elevated regulatory oversight increases market restraints but promises standardized quality and broader acceptance. Key Players - B. Braun - Baxter International - Johnson & Johnson (Ethicon) - BDCura Medical - Medtronic - CryoLife - Integra LifeSciences - Novatech - C.R. Bard (BD) - Terumo - Teleflex - Medline Industries - Biocomposites - Biom’Up - Omrix Biopharmaceuticals ‣ Absorbable Hemostats Market: https://www.coherentmi.com/industry-reports/absorbable-hemostats-market

Anti CD47 Drugs Market Outlook: Growth, Trends, Forecast The anti CD47 drugs industry is experiencing an inflection driven by breakthroughs in macrophage-mediated immunotherapy and strategic biomarker integration. Detailed market insights indicate that robust business growth and evolving industry trends are reshaping treatment paradigms for hematologic and solid tumor segments. Advanced clinical pipelines and expanded market research are fueling an aggressive market growth trajectory around the globe. Market Size and Overview The anti CD47 drugs market is estimated to be valued at USD 0.20 Bn in 2025 and is expected to reach USD 2.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 43.1% from 2025 to 2032. Recent Anti CD47 Drugs Market report underscores expanding industry size and industry share potential, fueled by high unmet need in defined market segments. This jump in market revenue reflects growing market opportunities across hematologic malignancies and solid tumors, even as market challenges around safety profiles are addressed via adaptive designs. The market forecast further highlights robust business growth driven by combination regimen market trends. Use Case Scenarios As per the latest market report and market analysis, several high-impact implementation cases have emerged: • Bristol Myers Squibb’s BMS-986012 combination trial in AML (Q3 2024) delivered a 30% complete remission rate, aligning with Anti CD47 Drugs Market trends toward personalized regimens and showcasing a key market driver. • ALX Oncology’s ALX148 plus pembrolizumab pilot in metastatic solid tumors achieved a 25% PFS improvement in early 2025, demonstrating seamless integration benefits in core market segments. • Innovent Biologics reported a 40% tumor reduction with IBI188 in non-Hodgkin’s lymphoma (H2 2024), highlighting market opportunities identified in recent market analysis. Policy and Regulatory Impact • In March 2025, the US FDA granted Orphan Drug Designation for BMS-986012, streamlining approval and mitigating key market restraints related to clinical trial costs. • July 2024’s EMA guidance update on immuno-oncology combinations broadened Anti CD47 Drugs Market share potential in Europe, recalibrating market dynamics under international standards. • China’s NMPA priority review pathway for novel biologics (Dec 2024) reduced entry barriers and expanded market scope, bolstering business growth across the Asia-Pacific region. Key Market Players • Bristol Myers Squibb • ALX Oncology • Trillium Therapeutics • Innovent Biologics • Forty Seven (Gilead Sciences) • Merck & Co. • Roche • Novartis • Amgen • Pfizer • Johnson & Johnson • AstraZeneca These market companies are vying for leadership in immuno-oncology. ‣ Anti CD47 Drugs Market: https://www.coherentmi.com/industry-reports/anti-cd47-drugs-market

Astrocytoma Drug Market Growth, Trends, and Forecast The Astrocytoma Drug Market is experiencing accelerated development as advanced therapeutics target aggressive brain tumors. Increasing R&D collaboration between pharmaceutical innovators and academic centers in 2024–2025 is reshaping industry size projections and driving robust business growth. Evolving market dynamics and strategic licensing agreements are central to this momentum. Market Size and Overview The Global Astrocytoma Drug Market size is estimated to be valued at USD 1.76 Bn in 2025 and is expected to reach USD 3.10 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.4% from 2025 to 2032. Emerging Astrocytoma Drug Market trends include personalized immuno-oncology approaches and gene-targeting compounds. The latest Astrocytoma Drug Market report underscores rising R&D investments and strategic licensing deals that expand market scope and diversify market revenue channels. Shifting Astrocytoma Drug Market share dynamics are observed as late-stage candidates advance toward regulatory approval. Use Case Scenarios - Roche’s 2024 Phase I/II trial of combined PD-1 inhibitor and temozolomide in Europe delivered a 25% increase in progression-free survival, showcasing enhanced therapeutic synergy and accelerating market growth. - Novartis implemented real-world integration of AI-driven imaging diagnostics with targeted therapy in US neuro-oncology centers in early 2025, achieving a 40% reduction in diagnostic timelines and reinforcing market drivers tied to precision medicine. - Bristol Myers Squibb’s compassionate use program across Asia-Pacific in late 2024 facilitated access to experimental CDK4/6 inhibitors for 120 astrocytoma patients, yielding positive quality-of-life metrics and expanding market opportunities in emerging regions. Policy and Regulatory Impact - In 2024, the FDA’s Oncology Center of Excellence granted expedited review pathways for novel astrocytoma candidates, reducing approval timelines by six months and mitigating key market challenges. - The 2025 EMA guidance on orphan drug designation for rare brain tumors introduced incentives such as fee waivers and extended exclusivity, bolstering market drivers and revenue potential. - China’s NMPA adopted a real-world evidence framework in mid-2024 for astrocytoma treatments, enabling local clinical bridging studies and accelerating market entry, though introducing new market restraints on post-approval surveillance. - In early 2025, WHO released updated international standards on neuro-oncology trial design, harmonizing endpoints and supporting global regulatory convergence to ease market access barriers. Key Players Our market analysis identifies the following key companies leading innovation and commanding industry share in the Astrocytoma Drug Market: • F. Hoffmann-La Roche Ltd. • Novartis AG • Pfizer Inc. • Bristol Myers Squibb • AbbVie Inc. • Merck & Co., Inc. • Eli Lilly and Company • AstraZeneca plc • Johnson & Johnson • Bayer AG • Amgen Inc. • Takeda Pharmaceutical Company Limited ‣ Astrocytoma Drug Market: https://www.coherentmi.com/industry-reports/astrocytoma-drug-market

RNA Therapeutics Market Revolution: Growth, Insights & Trends The RNA Therapeutics Market is accelerating the shift toward precision medicine by leveraging mRNA and RNA interference platforms. Recent advances in lipid nanoparticle delivery and self-amplifying constructs have reshaped industry size projections and competitive dynamics. Proprietary analysis underpins all projections and strategic observations herein. Market Size and Overview - The RNA Therapeutics Market is estimated to be valued at USD 4.2 Mn in 2025 and is expected to reach USD 160.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 68.2% from 2025 to 2032. - Forecasts from our proprietary analysis highlight that accelerated clinical pipelines and scalable manufacturing capacity will drive robust market revenue expansion. - Recent market size and market report findings underscore surging investments in next-generation delivery systems, enhancing market trends across North America and Asia-Pacific. - This RNA Therapeutics Market report also calls out intensified licensing activity and strategic M&A as critical market drivers. Use Case Scenarios - Oncology immunotherapies at Gritstone Bio (2024) achieved a 45% response-rate uplift in a Phase II melanoma trial, demonstrating how self-amplifying RNA constructs unlock new market revenue channels. - Cardiovascular RNAi treatments deployed by HDT Bio in APAC hospitals (Q1 2025) delivered a 30% LDL-cholesterol reduction, validating rapid scale-up and expanding RNA Therapeutics Market trends in emerging economies. - Rare disease applications by Arcturus Therapeutics (late 2024) leveraged targeted mRNA delivery to restore enzyme function, illustrating meaningful improvements in patient outcomes and reinforcing market share growth. Policy and Regulatory Impact - The FDA’s 2024 guidance on mRNA stability introduced stringent validation requirements, serving as a market restraint but boosting analytical rigor across R&D pipelines. - EMA’s 2025 harmonized standard for lipid nanoparticle carriers streamlined cross-border approvals, supporting key market drivers and refined market growth strategies. - China’s NMPA rolled out conditional-approval pathways in late 2024, expanding market scope for domestic RNA Therapeutics Market share and fostering onshore manufacturing hubs. - WHO’s 2025 update to ICH Q5A guidelines addressed viral vector impurity limits, reducing global market challenges and improving compliance frameworks. Key Players - Key market companies and market players in the RNA Therapeutics sector include: Alphavax; Arcturus Therapeutics; Atyr Pharma; Gritstone Bio; HDT Bio; Moderna; BioNTech; CureVac; Ionis Pharmaceuticals; Alnylam Pharmaceuticals; Translate Bio; and Sarepta Therapeutics. - 2024 partnership: Arcturus Therapeutics collaborated with Apeiron Biologics on self-amplifying RNA vaccine co-development, accelerating clinical entry and reinforcing its global footprint. - 2025 regulatory approval: Moderna secured EMA clearance for its mRNA-based influenza candidate, marking a pivotal broadening of approved indications under new guidelines. - 2024 market-entry expansion: Alnylam Pharmaceuticals inked a licensing deal with a Singapore biotech firm, boosting local production and enhancing regional market analysis capabilities. ‣ RNA Therapeutics Market: https://www.coherentmi.com/industry-reports/rna-therapeutics-market

Single Use Downstream Bioprocessing Market Trends and Forecast 2025-2032 Market insights reveal strong momentum in the Single Use Downstream Bioprocessing Market as biopharmaceutical developers prioritize scalable, contamination-resistant operations. Industry size expansion is fueled by rising demand for monoclonal antibody downstream processing and gene therapy manufacturing. Business growth projections and recent market research underscore robust market opportunities across developing economies, reflecting key industry trends. Market Size and Overview The single use downstream bioprocessing market is estimated to be valued at USD 1.74 Bn in 2025 and is expected to reach USD 4.71 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2032. According to the Single Use Downstream Bioprocessing Market report, increasing investment in disposable chromatography and membrane filtration is a key market driver. Market revenue for single-use tangential flow filtration systems surpassed USD 450 million in 2024, while market share analyses show a 10% shift toward novel polymer-based consumables, reflecting evolving market trends. The market forecast underscores opportunities in emerging segments like bioreactor-linked purification skids, reflecting robust market growth trajectories. Use Case Scenarios - Rapid vaccine production integration: In Q4 2024, a global CDMO deployed a single-use chromatography-and-filtration skid, reducing purification cycle time by 30% and boosting process yields by 20%, translating into an estimated Single Use Downstream Bioprocessing Market revenue uplift of 8%. - Monoclonal antibody facility expansion: In mid-2025, a biotech firm adopted single-use depth filters at a commercial mAb plant, cutting CIP downtime by 40% and water use by 25%, highlighting market growth strategies and addressing supply chain market challenges for sustainable operations. - Cell and gene therapy workflows: A 2024 collaboration integrated single-use tangential flow filtration into viral vector downstream processing, achieving a 15% rise in viral titers and ensuring compliance with evolving EMA guidelines, showcasing how these integrations reshape market dynamics in gene therapy manufacturing. Policy and Regulatory Impact - In 2024, FDA released updated guidance on disposable system validation, emphasizing extractables and leachables testing, driving key market drivers for advanced polymer characterization. - The European Medicines Agency (EMA) introduced new single-use biocontainer traceability requirements in early 2025, tightening market restraints and boosting demand for barcoding-enabled modules. - ISO 13408 revision in 2024 incorporated specific risk assessment protocols for single-use assemblies, expanding market scope and new market segments while reinforcing market analysis standards. - In Q3 2025, China's NMPA approved revised Good Manufacturing Practices for sterile disposable systems, unlocking significant market opportunities across Asia. Key Players Based on comprehensive market research and market report insights, the following market companies are identified as key market players: • 3M • Agilitech • CPC (Colder Products Company) • Cytiva Lifesciences • Pall Corporation • Thermo Fisher Scientific • Sartorius AG • Danaher Corporation • GE Healthcare • Repligen Corporation • Parker Hannifin Corporation • Meissner Filtration Products • Eppendorf AG • Merck KGaA • Herose GmbH ‣ Single Use Downstream Bioprocessing Market: https://www.coherentmi.com/industry-reports/single-use-downstream-bioprocessing-market

Blockchain Technology in Healthcare Market Growth and Trends The Blockchain Technology in Healthcare Market is undergoing rapid transformation as decentralized ledgers enhance data security and patient trust. Leading blockchain vendors are capturing significant industry share by focusing on secure consent management and interoperability. Expert market analysis highlights that evolving health IT architectures are expanding the industry size and driving robust business growth. Market Size and Overview The blockchain technology in healthcare market is estimated to be valued at USD 194.5 Mn in 2025 and is expected to reach USD 796.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 22.3% from 2025 to 2032. According to the latest Blockchain Technology in Healthcare Market, surging investments in secure data sharing are among the primary market drivers. The Blockchain Technology in Healthcare Market revenue trajectory reflects partnerships between tech vendors and hospital networks, amplifying service integration. Emerging Blockchain Technology in Healthcare Market trends include AI-enabled smart contracts and cross-border data exchanges. This market size growth is further fueled by rising telemedicine adoption and secure consent mechanisms. Recent market report analyses emphasize shifts in reimbursement models and data monetization strategies. Despite consolidation, market share concentration remains moderate, indicating room for new entrants. Projected market revenue uplift aligns with increased public funding for health IT modernization. Use Case Scenarios • Pharmaceutical supply chain integrity: In mid-2024, a leading global pharmaceutical company piloted blockchain-based cold-chain tracking, reducing counterfeit incidents by 40% and accelerating recall processes by 25%. • Patient data management: Late-2024 saw a regional hospital network deploy a blockchain identity solution, cutting data breach incidents by 60% and streamlining consent audits across 15 clinics. • Clinical trials optimization: Early 2025, a biotech firm implemented smart-contract-driven trial enrolment, trimming administrative overhead by 30% and speeding protocol amendments by 18%. Policy and Regulatory Impact • EU EHR Interoperability Guidelines (July 2024) now mandate blockchain audit trails for patient records, prompting healthcare providers to allocate 15% more budget toward compliance. • US FDA Draft Guidance on Distributed Ledger Tech (Q1 2025) clarifies validation frameworks for blockchain in clinical trials, reducing time-to-approval by 20%. • ISO 22739:2025 Update standardized blockchain terminology in healthcare, facilitating cross-border data exchange and widening the market scope for global vendors. • South Korea’s Health Data Act (Dec 2024) introduced incentives for blockchain-secured patient registries, driving regional market growth by an estimated 12%. Key Players 1. ConsenSys 2. Embleema 3. Equideum Health 4. IBM Life Sciences 5. MELLODDY 6. Guardtime 7. BurstIQ 8. Chronicled 9. Simply Vital Health 10. Solve.Care 11. PokitDok 12. Medicalchain 13. FarmaTrust 14. VeChain 15. Modum 16. Iryo ‣ Blockchain Technology in Healthcare Market: https://www.coherentmi.com/industry-reports/blockchain-technology-in-healthcare-market